GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lunai Bioworks LNAI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.17

-30.11%

Close of 29 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$51,992

FY2017FY2026

Net income

−$3.6m

FY2017FY2026

Free cash flow

−$5.29bn

FY2017FY2026

Shareholders' equity

−$9.02bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$51,992—————————
Gross profit−$41,530−$129,094———−$391,416————
Research and development$24.5m$537,428$2.7m$4.2m$8.4m$15.5m$4.7m$2.5m$620,000$60,000
Operating income−$7.9m−$18.5m−$81.6m−$38.6m−$116.1m−$23.4m−$11.9m−$11.0m−$5.3m−$2.4m
Net income−$3.6m−$178.0m−$88.4m−$39.7m−$113.4m−$26.7m−$11.4m−$18.0m−$6.3m−$2.1m
Diluted earnings per share-0.77-60.65-43.71-48.21-113.43-26.72-2.46-4.79-2.87-1.74

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$9.94bn$8.2m$163.1m$58.3m$84.6m$189.6m$178.1m$179.9m$182.5m$4.5m
Cash and short-term investments$1.71bn$480,551$220,467$1.9m$9.2m$20.7m$8.7m$12.3m$15.6m$3.9m
Total liabilities$18.97bn$29.6m$31.2m$11.8m$12.0m$14.9m$11.8m$6.8m$23.8m$3.0m
Debt$1.34bn$10.2m$3.8m$5.6m$7.0m$7.4m$5.8m——$2.1m
Shareholders' equity−$9.02bn−$21.3m$132.0m$46.5m$72.6m$174.7m$166.3m$173.1m$158.7m$1.5m
Shares outstanding5m3m2m1m1m1m5m4m2m1m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$5.29bn−$7.9m−$11.0m−$11.8m−$15.7m−$20.6m−$10.5m−$8.5m−$4.3m−$1.2m
Capital spending−$1.2m−$3−$70,430−$29,774−$5,156−$48,887−$180,000−$720,000−$30,000—
Free cash flow−$5.29bn−$7.9m−$11.0m−$11.8m−$15.7m−$20.7m−$10.6m−$9.2m−$4.4m−$1.2m

Latest quarters

By quarter end

Sept 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$31,050$20,942——————
Gross profit$1,383$9,941−$11,332−$41,522−$32,626———
Operating income−$2.1m−$1.4m−$1.8m−$2.5m−$4.1m−$4.2m−$4.5m−$53.3m
Net income−$2.0m−$2.6m−$1.8m$2.8m−$126.7m$189,176−$7.3m−$44.2m
Diluted earnings per share-0.44-0.56-0.610.96-43.180.06-3.59-21.86
Cash from operations−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$2.0m−$2.0m
Total assets$9.94bn$9.9m$6.7m$7.0m$8.2m$117.7m$111.3m$121.8m
Cash and short-term investments$1.71bn$3.2m$491,645$624,808$480,551$1.6m$311,764$220,571
Debt$1.28bn$1.3m$2.5m$2.4m$9.7m$6.5m$5.7m$3.1m
Shareholders' equity−$9.0m−$9.6m−$13.5m−$13.0m−$21.3m$88.4m$82.1m$98.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——2.7%
Operating income-41.1%-19.6%14.0%
Net income-55.2%-33.2%7.4%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-0.2-0.1-0.6-0.7-0.1-1.8-7.8-6.8-15.9
Price to sales14.6————————

Share price return

Finished calendar years

20252024202320222021202020192018
Return-94%54%152%-73%156%-50%-1%7%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 8-to-1 reverse split · 22 May 2026
  • 10-to-1 reverse split · 30 Sept 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.